If you have MHSPC (metastatic hormone sensitive to prostate cancer, when cancer still responds to hormone therapy) and are different in good enough health; The last thing you want to do is to adequately treat your cancer.
And yet: Thousands of Americans Men do not receive the care template for MHSPC. Their cancer is undergoing treatment – but This is a stable problem! The best treatment is available today, covered by Medicare and most insurance and recently adopted legislation will make this care even more affordable.
Recent interview with Medical Oncologist Neeraj Agarwal, MD, of the Huntsman Institute of Cancer of the University of Utah for the Prostate Cancer Foundation website. Agarwal is an internationally recognized physician-scientist in the field of prostate cancer and the management of metastatic disease. He is also a clinical physician who wants to help his patients live longer and maintain a better quality of life. When it comes to treatment of MHSPC, he says, “More is more. ” In other words, hit cancer hard early and come to it from multiple angles.
ADT alone is not enough
Many men with early metastatic prostate cancer are treated with ADT (androgen deprivation therapy, also known as hormonal treatment). ADT dramatically reduces male hormone testosteronewhich is prostate cancer guide – see below. But ADT alone is not enoughAgarwal says: “The care standard is Combined treatment. This means it gives ADT plus another type of hormonal treatment: Total androgen blockage with one androgen receptor inhibitor (ARPI).
This is a great deviation from the previous “let’s try this, and if it doesn’t work, let’s try this other approach.” So many years ago, the treatment of metastatic prostate cancer was like navigating a boat through a series of channels. Plan A was adt. Then, only After the cancer has progressedThe men proceeded to Plan B and then to drawing C, with ARPI and then chemotherapy, or vice versa.
Care Standard has changed
In 2015, the first of a series of folders were published and the treatment approach began to expand. What would happen if, instead of waiting for ADT to fail, we tried prolong the success of; What if we started giving these next step options earlier? Clinical Milestone Tests* showed the success of Giving combined treatment in front of early metastasis. Initial tests compared ADT Plus Docetaxel vs. ADT only. showed later tests Even more promising results Comparing ADT plus an arpi vs. ADT only. The results were so impressive that the combined treatment (ADT plus ARPI) is now the standard of care.
Which ARPI is best? “This has never been compared,” Agarwal says, “but most patients will go well eachARPI combined with ADT. If you look at the results of these studies it is impressive to see that Each ADT PLUS ARPI figure showed about one 30 to 40 percent decrease in risk of death. Some men can live for many years. We know that ADT plus an ARPI is a powerful combination. Based on the data, we should try to get a combined treatment for all patients with MHSPC. “The only exceptions, adds Agarwal, are men with other serious health problems that have no life expectancy over two years. For these men, only ADT is sufficient,” but this is a very small number of patients. “
The Guidelines of National Comprehensive Cancer Network (NCCN) for men with MHSPC were updated in 2023 to recommend pair (Adt plus one arpi) and even triplets Treatment (ADT plus an ARPI PLUS ECORATH with Docetaxel) in front. In addition, for selected men, NCCN is the external beam radiation to the prostate if there are only a few metastases, also known as a low volume or oligomotystasy disease.
“Just a decade ago, the average survival for men with MHSPC (who were first treated with ADT only) was 32 to 36 months,” Agarwal says. (Note: This means that half of the patients died this time.) “When Docetaxel was transferred to the first line regulation (given with ADT early), this improvement of survival significantly. When Arpis – Enzalutamide, Abiraterone, Apalutamide, Darolutamide – Effectiveness.
But wait – I’m just on ADT! Is it too late to start combined treatment?
No, it’s not! If you are recently diagnosed with MHSPC, talk to your doctor about combination treatment as well as radiation if you need it. If you have MHSPC and you are only on ADT now, it’s not too late! Talk to your doctor about adding an ARPI with or without docetaxel now.
*These milestone tests and publications included charted, latitude, stampede, titan, enzamet and arches.
–
For your report:
It’s alphabet soup! Here is a renewal in all these abbreviations
Shooting It represents androgen deprivation therapy. Androgens are male hormones and the main male hormone is testosterone. ADT (drugs like Leuprolide and Degarelix) closes testosterone. However…
Prostate cancer is sneaky! It can start making its own androgen bootleg. So one Total androgen blockade – Get rid of all androgens – it is a more thorough approach, which has been proven to many landmarks to work better than ADT only.
Androgen blockage is best achieved with drugs called ARPIS, For inhibitors of androgen receptor inhibitors. This fairly new category of drugs includes enzalutamide, abiraterone, Apalutamide and Darolutamide. (You can also see those mentioned as drugs that block AR.)
There are also abbreviations for metastatic prostate cancer itself. A big problem with prostate cancer is that they are heterogeneous. It is a mixture of many different types of cells. Most of these cells respond to hormonal therapy, but not all. Over time, cells that do not respond to hormonal therapy can exceed those that respond to it.
Early metastasis is called MHSPCFor metastatic hormone sensitive (vulnerable to hormone therapy) prostate cancer.
Subsequent metastasis is known as CRPCfor castration resistant (no longer responds to the lack of testosterone testosterone). However, some doctors call this Hip (Independent hormone or -sensitive prostate cancer).
There is also oligometry, as we discussed here and elsewhere on this site: only a few metastasis points, which can be treated with SBBT radiation.
In addition to the book, I have written about this story and much more about prostate cancer on the prostate cancer website, Pcf.org. The stories I wrote are under the categories, “understanding prostate cancer” and “for patients”. As we have said for years Patrick Walsh; Knowledge is power: Saving your life can start with the transition to the doctor and know the right questions you need to ask. I hope all men put prostate cancer on their radar. Take a basic PSA blood test in the early 1940s and if you are African descent or if the cancer and/or prostate cancer runs to your family, you should regularly examine for the disease. Many doctors do not do this, so it is up to you to ask for it. NOTE: I am a subsidiary of Amazon, so if you click on the link and buy a book, I will theoretically make a small amount of money.
© Janet Farrar Worthington
